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Abstract
Background: Nasal NK/T cell lymphoma is an aggressive disease and has a poor prognosis. Nasal NK/T
cell lymphoma is refractory to conventional chemotherapy and has strong tendency of widespread relapse
or dissemination into distant sites.
Methods:  We immunohistochemically studied nasal NK/T-cell lymphoma to elucidate the unique
characteristics of nasal NK/T-cell lymphoma, such as its higher metastatic tendency and its vast necrosis
which leads to destruction of the involved tissues. The expression of P-glycoprotein and MMP-9 was
evaluated in the 20 patients with nasal NK/T-cell lymphoma and 25 with nasal non-NK/T-cell lymphoma
and the relationship between expression of these proteins and clinical results were analyzed in this report.
Results: Overall 5-year survival rates for patients with nasal NK/T cell lymphoma, and nasal non-NK/T
cell lymphoma were 51%, and 84%. Distant involvement free 5-year survival rates for patients with nasal
NK/T cell lymphoma, and nasal non-NK/T cell lymphoma were 53%, and 79%.
Overall positivity for P-glycoprotein was observed in 10 of 19 patients with NTL and in 13 of 23 patients
with non-NTL. When the overall survival rate was compared between patients with P-glycoprotein
positive and negative, there was no difference between them.
Sixteen of the 19 patients with nasal NK/T cell lymphoma expressed MMP-9. In contrast, only 8 of the 22
patients with nasal non-NK/T cell lymphoma expressed MMP-9. Distant involvement free 5-year survival
rates for patients with MMP-9 negative, and MMP-9 positive were 92%, and 61%, respectively. The
difference was statistically significant (p = 0.027).
Conclusion: Positive immunoreactivity for P-glycoprotein was not an independent prognostic factor in
nasal NK/T-cell lymphomas, which stresses the importance of exploring other mechanisms of drug
resistance. The strong expression of MMP-9 is uniquely characteristic of nasal NK/T cell lymphoma and
may contribute to its strong tendency to disseminatate and the extensive necrosis which is always seen.
However, our results are based on univariate comparisons, and as such, should be viewed with some
caution.
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Background
Extranodal NK/T-cell lymphoma, nasal type (nasal NK/T
cell lymphoma) is characterized by progressive, unrelent-
ing ulceration, and necrosis of the nasal cavity and mid-
line facial tissues. This subtype of lymphoma, categorized
as angiocentric lymphoma in the Revised European-
American Lymphoma (REAL) classification [1], has been
renamed extranodal NK/T-cell lymphoma, nasal type in
the new WHO classification of lymphoid neoplasms [2].
This type of lymphoma is rare in the United States and
Europe but common in Asia [3-6]. The prognosis of Asian
population as well as Central American population is not
so poor as European population [7]. Phenotypically, this
lymphoma is characterized by expression of NK cell
marker CD56, lack of expression of surface CD3, infre-
quent expression of T-lineage markers other than CD2,
absence of T-cell receptor rearrangement, and strong asso-
ciation with Epstein-Barr virus (EBV) [6,8].
Nasal NK/T cell lymphoma is an aggressive disease and
has a poor prognosis. One of reasons for the poor progno-
sis of nasal NK/T cell lymphoma is that NK/T-cell lympho-
mas are refractory to conventional chemotherapy [9-11].
Doxorubicin-containing chemotherapy regimens gener-
ally appear less efficacious, either as an initial treatment or
as a salvage treatment for relapsed lesions in the manage-
ment of NK/T-cell lymphoma patients [10]. The ineffec-
tiveness of chemotherapy for such lymphoma types can
be partly explained by the presence of the multi-drug
resistance (MDR) phenotype, which confers cellular
resistance to a variety of unrelated anticancer agents [10-
12]. Despite accumulating experimental evidence that
high levels of P-glycoproteins are commonly expressed in
malignant tumor cells of various types of NK-neoplasms
[12,13], convincing data is very limited, largely due to the
rarity of these types of lymphomas [14].
Another reason for the poor prognosis of nasal NK/T cell
lymphoma is its strong tendency of widespread relapse or
dissemination into distant sites. Essential steps in the
process of tumor invasion and metastasis include the deg-
radation of the extracellular matrix (ECM) and basement
membrane (BM). The invasion of the BM by tumor cells is
thought to be one of the critical steps in metastasis, which
includes sequential multistep processes [15]. Many prote-
olytic enzymes degrade components of the ECM and BM
[16,17]. Among these, the matrix metalloproteinases
(MMPs) are attractive candidates as enzymes required for
tumor metastasis. The MMPs contain a zinc ion at their
active sites and can degrade native collagens and other
ECM components [18,19]. The MMP family includes four
types of collagenase (MMP-1, -8, -13, and -18), three types
of stromelysin (MMP-3, -10, and -11), and the 72- and 92-
kDa type IV gelatinases or collagenases (MMP-2 and
MMP-9). As type IV collagen is one of the integral compo-
nents of BM, the uncontrolled expression of two type IV
collagenases, MMP-9, is believed to play a critical role in
the invasion of BM by tumor cells [20]. The release of
MMP-9 has been associated with metastasis in a variety of
model systems [21-24]. MMP-9 can be also responsible
for chemoresistance of NK/T-cell lymphoma. Higher
expression of MMP-9 could result in tissue necrosis due to
more angiodestruction. Poor drug delivery owing to tissue
necrosis might be an important contributory factor [8].
In the current study, we performed an immunohisto-
chemical study of the expression of P-glycoprotein and
MMP-9 in nasal NK/T-cell lymphoma and other types of
nasal lymphomas (non-NK/T cell lymphoma) to eluci-
date the unique characteristics of nasal NK/T-cell lym-
phoma, such as its resistance of chemotherapy and strong
metastatic tendency.
Methods
Population
A total of 45 patients with nasal lymphoma were treated
in our institution between January 1980 and December
2005. The patient population consisted of 20 patients (10
men, 10 women) with nasal NK/T cell lymphoma, and 25
patients (12 men, 13 women) with nasal non-NK/T cell
lymphoma (Table 1). Cases with nasal non-NK/T cell
lymphoma consisted of 18 patients with diffuse large B-
cell lymphoma, one with B-cell small lymphocytic lym-
phoma, 3 with peripheral T-cell lymphoma, unspecified,
one with follicular lymphoma, adult T-cell Lymphoma,
and anaplastic large cell, T-cell lymphoma according to
the WHO classification system. Patients were usually fol-
lowed every 2 months for the first 2 years and every 3 to 5
months subsequently. Physical and endoscopical exami-
nation were performed at every visit and CT were usually
performed every 6 months. The median follow-up period
of surviving patients was 94 months.
Table 1: Characteristics of patients
NTL non-NTL
Patient number 20 25
Median age (range) 56 (27–74) 59 (21–81)
Sex (male:female) 10:10 12:13
Stage
I1 4 1 4
II 4 6
III, IV 2 4
B symptoms 14 2
Yes 14 2
No 6 23
EBER
Yes 18 6
No 2 19BMC Cancer 2007, 7:229 http://www.biomedcentral.com/1471-2407/7/229
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Treatment of the primary tumor
The radiation portal encompassed only clinically involved
areas with a generous margin in most patients and pro-
phylactic irradiation to the neck and supraclavicular
lymph nodes was not usually performed. The median
dose received was 40 Gy (range 9–74 Gy). The radiation
doses were heterogeneous because the radiation was inter-
rupted in 2 patients with nasal NK/T cell lymphoma due
to deterioration of general condition and becuase in 1990
the standard radiation dose was increased from 40 Gy to
50 Gy for patients with nasal NK/T cell lymphoma.
From 1980 to 1986, radiation therapy alone was the pri-
mary treatment, although adjuvant chemotherapy was
given to some patients. Since 1987, a combination of radi-
otherapy and chemotherapy has been the standard treat-
ment. The main chemotherapy combinations before 1985
did not include adriamycin, e.g. COP (cyclophospha-
mide, vincristine, and prednisolone) or VEMP (vincris-
tine, cyclophosphamide, methotrexate and
prednisolone). These were administered after radiother-
apy. Most patients from 1985 on received CHOP (cyclo-
phosphamide, doxorubicin, vincristine, and
prednisolone), VEPA (same drugs as CHOP, but doses
and treatment schedule were different), or MACOP-P
(methotrexate, doxorubicin, cyclophosphamide, vincris-
tine, prednisolone, and pepleomycin) had been used
before and after radiotherapy since 1989.
Statistical Analysis
All but 3 surviving patients had a minimum follow-up of
2 years and the follow-up periods of the other 3 patients
were, 1, 1, and 4 months. The median follow-up of surviv-
ing patients was 94 months. Survival rates of the patients
were measured using the Kaplan-Meier method. The over-
all survival was calculated from the date when the treat-
ment started to the time of death or last follow-up. The
distant involvement free survival was calculated from the
date when the treatment started to the time of diagnosis
of distant metastasis or last follow-up. Statistical signifi-
cance was compared by the log rank test.
Immunohistochemical Examination
All of the biopsies were taken at the initial time of the
diagnosis. Immunohistochemical staining was carried out
with methods previously described [25]. All of the biop-
sies were taken at the initial time of the diagnosis. We used
biopsy samples of 43 patients and samples of 3 patients
were not evaluable because they were too tiny. Immuno-
histochemical staining was carried out using the avidin-
biotin-peroxidase complex method.
Immunohistochemical detection was performed using
the following monoclonal antibodies: antihuman MMP-9
(56-2A4, Daiichi Fine Chemical Co., Ltd., Japan)(1: 200
dilution), and MDR/P-glycoprotein antibody (C-494,
Dako; 1:100 dilution). Normal mouse serum was substi-
tuted for primary antibodies as a negative control.
The specificity and selectivity of antibody of MMP-9 was
proved by Fujimoto et al. and this manufacturer [26]. For
MMP-9, tumors that contained at least focally moderate
to strong immunoreactivity were considered positive.
To detect P-glycoprotein, we selected mouse anti-human
C-494 antibody, which recognizes an internal epitope
located on the C-terminal domain of the P-glycoprotein
molecule, and which is encoded by two closely related
genes, MDR1 and MDR3. Tumors were considered posi-
tive for P-glycoprotein expression if the neoplastic cells
exhibited membrane staining greater than 10%, according
to a cutoff value that has been recommended in the
majority of immunohistochemical studies for B-cell lym-
phomas [27].
In situ hybridization
RNA-DNA in situ hybridization was performed on forma-
lin-fixed paraffin-embedded tissue sections using the
biotinylated synthetic DNA probe as previously described
with modifications [28]. Briefly, the biotinylated probe
was an oligonucleotide DNA complimentary to EBER1
sequence that was chemically labeled with 6 biotin mole-
cules (5'-CCCTAGCAAAACCTCTAGGGCAGC-(TAG)5-
BBB-(TAG)2-BBB-3'). The hybridization signal was
detected by using ABC-peroxidase. The sections were then
counterstained with hematoxylin, dehydrated, mounted
with permount, and investigated under a light micro-
scope.
Results
Clinically, nasal NK/T cell lymphoma had unique features
characterized by destruction of the nasal cavity and mid-
line facial tissues caused by progressive and unrelenting
ulceration and necrosis of the involved tissues, as demon-
strated in Fig. 1. This destructive feature of nasal NK/T cell
lymphoma is very characteristic, and distinct from the
other types of malignant lymphoma, which form tumors
or cause swelling of the involved lymph nodes. A charac-
teristic feature is invasion of vascular walls and, usually
occlusion of lumina by lymphoid cells. The vascular
occlusion is usually associated with prominent ischemic
necrosis of both tumor cells and normal tissue.
Most patients (70%) with nasal NK/T cell lymphoma had
B symptoms, such as fever or unexplained loss of 10% or
more of their body weight in the six months before diag-
nosis. In contrast, only less than10% of patients with
nasal non-NK/T cell lymphoma had B symptoms (Table
1). EBER1 transcripts were detected in 18 of 20 patientsBMC Cancer 2007, 7:229 http://www.biomedcentral.com/1471-2407/7/229
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with nasal NK/T cell lymphoma (Table 1), indicating
strong association with Epstein-Barr virus (EBV).
Overall 5-year survival rates for patients with nasal NK/T
cell lymphoma, and nasal non-NK/T cell lymphoma were
51%, and 84% (p = 0.58), respectively (Fig. 2a). The clin-
ical courses were quite aggressive and nasal NK/T cell lym-
phoma patients have a higher incidence of widespread
extranodal involvement, even though their stage was only
I or II. Distant involvementfree 5-year survival rates for
patients with nasal NK/T cell lymphoma, and nasal non-
NK/T cell lymphoma were 53%, and 79% (p = 0.18),
respectively (Fig. 2b). The difference is not statistically sig-
nificant, however, this is most likely because of the small
sample size.
Within malignant cells, patterns of P-glycoprotein immu-
noreactivity generally were of membrane staining, but
cytoplasmic immunoreactivity was occasionally observed
in some tumor cells (Fig. 3a). When a staining distribu-
tion cutoff value of greater than 10% was used to classify
positive immunoreactivity, overall positivity for P-glyco-
protein was observed in 10 of 19 patients with NTL and in
13 of 23 patients with non-NTL (Table 2). When the over-
all survival rate was compared between patients with P-
glycoprotein positive and negative, there was no differ-
ence between them (p = 0.88) (Fig. 4). The similar result
was obtained, when this analysis was also done separately
for T and B cell lymphomas. The 5-year survival rate for P-
glycoprotein positive and negative in T cell lymphomas
was 68% and 67%. The 5-year survival rate for P-glycopro-
tein positive and negative in B cell lymphomas was 85%
and 71%.
To identify the localization of the MMP-9 gene product,
immunohistochemical staining was performed on biopsy
sections of patients with NK/T cell lymphoma and non-
NK/T cell lymphoma (Fig. 3b, Table 3). Sixteen of the 19
patients with nasal NK/T cell lymphoma expressed MMP-
9. In contrast, only 8 of the 22 patients with nasal non-
NK/T cell lymphoma expressed MMP-9. Immunohisto-
chemically, the MMP-9 gene product was localized in
lymphoma cells, macrophages, and neutrophils. All cells
that were positive for MMP-9 were intensely stained, indi-
cating that they expressed high levels of MMP-9. Cells
which expressed MMP-9 existed at the invasive edge of
tumor cell nests and the peripheral regions of the necrotic
zone in nasal NK/T cell lymphomas. Distant involvement
free 5-year survival rates were compared between patients
with MMP-9 positive and negative (Fig. 5). Distant
involvement free 5-year survival rates for patients with
MMP-9 negative, and MMP-9 positive were 92%, and
61%, respectively. The difference was statistically signifi-
cant (p = 0.027). The similar result was obtained, when
this analysis was also done separately for T and B cell lym-
phomas. Distant involvement free 5-year survival rates for
(a) The overall survival rates of patients of stage I or II with  nasal NK/T cell lymphoma and nasal non-NK/T cell lym- phoma Figure 2
(a) The overall survival rates of patients of stage I or II with 
nasal NK/T cell lymphoma and nasal non-NK/T cell lym-
phoma. (b) The distant involvement free rates of patients of 
stage I or II with nasal NK/T cell lymphoma and nasal non-
NK/T cell lymphoma.
There was a deep ulcer in the middle of the hard palate with  foul-smelling discharge (left photo) Figure 1
There was a deep ulcer in the middle of the hard palate with 
foul-smelling discharge (left photo). After radiotherapy, the 
tumor disappeared and deficit of the anterior palate 
appeared (right photo).BMC Cancer 2007, 7:229 http://www.biomedcentral.com/1471-2407/7/229
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patients with MMP-9 negative, and MMP-9 positive in T
cell lymphomas were 89%, and 57%, respectively. Distant
involvement free 5-year survival rates for patients with
MMP-9 negative, and MMP-9 positive in B cell lympho-
mas were 100%, and 62%, respectively.
Discussion
The overall outcome of nasal NK/T cell lymphoma is
poor, even if diagnosed in the early stage [9,29,30]. One
of the reasons for the poor prognosis of nasal NK/T cell
lymphoma is its resistance to chemotherapy. Cheung et al.
reported that of 61 patients who were administered chem-
otherapy, 31 showed disease progression while receiving
chemotherapy, of whom 17 progressed locoregionally.
They concluded that the addition of anthracycline-con-
taining chemotherapy to radiotherapy does not appear to
confer any survival benefit in stage I patients [8]. The rea-
sons for the resistance to chemotherapy are not clear. The
overexpression of MDR1 phenotype is considered one of
the major determinants for the ineffectiveness of chemo-
therapy in nasal NK/T-cell lymphoma patients [10,11].
However, there was no significant difference in overall
positivity for P-glycoprotein between NTL and non-NTL
The distant involvement free rates of patients with B and T- cell lymphomasof stage I or II with MMP9 positive or negative Figure 5
The distant involvement free rates of patients with B and T-
cell lymphomasof stage I or II with MMP9 positive or nega-
tive. All classifications of B and T-cell lymphomas were joined 
together and analyzed.
Table 2: Expression of P-glycoprotein according to WHO 
classification
positive negative
NTL 10 9
Peripheral T cell lymphoma, unspecified 2 1
Anaplastic large cell, T-cell lymphoma 0 1
Adult T-cell Lymphoma 1 0
DLBCL 8 8
Follicular lymphoma 1 0
B-cell small lymphocytic lymphoma 1 0
(a) Expression of P-glycoprotein in nasal NK/T cell lymphoma  (original magnification, ×200) Figure 3
(a) Expression of P-glycoprotein in nasal NK/T cell lymphoma 
(original magnification, ×200). (b) Expression of MMP-9 in 
nasal NK/T cell lymphoma (original magnification, ×200).
The overall survival rates of patients with B and T-cell lym- phomas of stage I or II with P-glycoprotein positive or nega- tive Figure 4
The overall survival rates of patients with B and T-cell lym-
phomas of stage I or II with P-glycoprotein positive or nega-
tive. All classifications of B and T-cell lymphomas were joined 
together and analyzed.BMC Cancer 2007, 7:229 http://www.biomedcentral.com/1471-2407/7/229
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in our study (Table 2). Positive immunoreactivity for P-
glycoprotein was not found to be an important prognostic
factor for patients' survival (Fig. 4). Kim et al. reported
similar results obtained by using the same antibody,
mouse anti-human C-494 antibody on paraffin-embed-
ded sections [14]. These results indicate that the frequent
expression of MDR (P-glycoprotein-positive) phenotype
may account for a certain proportion [12], but not all, of
the failure of chemotherapy [31]. Necrosis is also a con-
stant microscopical feature in nasal NK/T cell lymphoma,
usually with a zonal pattern of distribution that suggests a
vascular pathogenesis. Poor drug delivery owing to tissue
necrosis resulting from angiodestruction by nasal NK/T
cell lymphoma cells might be an important contributory
factor [8].
Another reason for the poor prognosis of nasal NK/T cell
lymphoma is its strong tendency to widespread relapse or
to disseminate into distant sites. Common sites of distant
involvement during progression of the disease were sys-
temic lymph nodes, lung, liver, spleen, skin, and gastroin-
testinal tracts [32]. We found that most patients with
nasal NK/T cell lymphoma expressed high levels of MMP-
9. Release of MMP-9 enables tumor cells to invade
through basement membranes of blood vessels and lym-
phatics, thereby initiating metastatic spread [16,33]. Thus,
the strong expression of MMP-9 in nasal NK/T cell lym-
phoma may explain its strong tendency to metastasize.
We also reported the expression of MMP9 in 158 patients
with non-Hodgkin's lymphomas [34]. Almost all of the
patients with nasal NK/T cell lymphoma and anaplastic
large-cell lymphoma expressed MMP9. In this study, 15 of
17 (88%) patients of nasal NK/T cell lymphoma expressed
MMP9. Five of 8 (63%) of peripheral T-cell lymphomas,
unspecified expressed MMP9 and 4 of 4 (100%) of
peripheral T-cell lymphomas, unspecified expressed
MMP9. In contrast, only a small fraction of the patients
with exranodal marginal zone B-cell lymphoma of
mucosa-associated lymphoid tissue type and follicular
lymphomas expressed MMP9. About 50% of the diffuse
large B-cell lymphomas (DLBCL) expressed MMP9. Over-
all survival rates of patients who expressed MMP9 were
significantly lower than those who did not.
Inhibition of the function of MMPs is being pursued for
anticancer therapy. TIMPs (tissue inhibitors of metallo-
protease) were first compounds to be considered for clin-
ical development. However, the lack of effective methods
of systemic gene delivery has limited the clinical utility of
this approach, whereas the development of synthetic
inhibitors of MMPs has been actively pursued and widely
tested in clinical trials [35].
Progress in the treatment for nasal NK/T lymphomas has
been slow due to the rarity of the diseases, geographic var-
iation, relative chemoresistance, and lack of randomized
trials. There is no consensus about o  ptimal therapy and
recommendations are based on anecdotal reports, small
series, and phase II trials. There is general agreement that
results with CHOP alone are so poor in adults with most
peripheral T/NK cell lymphomas [36]. So, the combined
radiotherapy and chemotherapy was used [37]. We previ-
ously reported 65 patients with mature T/NK-cell lympho-
mas treated with radiotherapy between 1983 and 2002 to
analyze the influence of radiotherapy doses and chemo-
therapy doses and clinical parameters on in-field disease
control in order to assess the optimal radiation doses for
treatment of mature T/NK-cell lymphomas [38]. There
were no significant differences in radiosensitivity among
subtypes of mature T/NK-cell lymphomas, at least
between nasal NK/T cell lymphoma and peripheral T-cell
lymphomas, unspecified. Radiation doses of 50 Gy or
more may be required to obtain in-field control of mature
T/NK-cell lymphomas [38].
Conclusion
In conclusion, positive immunoreactivity for P-glycopro-
tein was not an independent prognostic factor in nasal
NK/T-cell lymphomas. Although the role of strong MMP-
9 expression in the spread of nasal NK/T cell lymphoma
has yet to be definitely established, our findings demon-
strated that MMP-9 may be related to a strong tendency to
metastasize and the locally destructive nature of nasal NK/
T cell lymphoma. However, our results are based on uni-
variate comparisons, and as such, should be viewed with
some caution.
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